Bioton sale talks continue to be postponed
Puls Biznesu reported that negotiations concerning the sale of biotech company Bioton will be delayed through to the middle of January. "Another postponement of the transaction is not a good sign for Bioton. Previously it could be assumed that Jerzy Starak is awaiting Q3 results or a decision on registering interferon beta. [...] It all seems that talks concern lowering the price," said Paweł Burzyński, analyst with DM BZ WBK.
At the end of August Jerzy Starak and Ryszard Krauze announced that they will pay zł.450 million for one third of Bioton shares and another zł.50 million after registering the new pharmaceutical. "A bear oil market and lack of success of Petrolinvest drastically limits his access to cash [Ryszard Krauze], especially in times of the financial crisis. This means that in negotiations concerning Bioton, Ryszard Krauze might have no other choice," said Paweł Burzyński.
Source: Puls Biznesu (M.M.)
At the end of August Jerzy Starak and Ryszard Krauze announced that they will pay zł.450 million for one third of Bioton shares and another zł.50 million after registering the new pharmaceutical. "A bear oil market and lack of success of Petrolinvest drastically limits his access to cash [Ryszard Krauze], especially in times of the financial crisis. This means that in negotiations concerning Bioton, Ryszard Krauze might have no other choice," said Paweł Burzyński.
Source: Puls Biznesu (M.M.)
